# About SPINRAZA (nusinersen)
Keywords: SPINRAZA, nusinersen, SMA, 5q spinal muscular atrophy, antisense oligonucleotide, SMN protein, motor neuron loss

> SPINRAZA is the first approved treatment for 5q spinal muscular atrophy (SMA), designed to increase functional survival motor neuron (SMN) protein and address the underlying cause of motor neuron loss.

## Details
- [SPINRAZA Mechanism of Action](#): SPINRAZA works by targeting SMN2 pre-messenger RNA to produce functional, full-length SMN protein.
- [Adverse Event Reporting](#): Information on reporting adverse events in the UK and Ireland is provided, including contact details for Biogen and regulatory agencies.
- [Clinical Study Programme](#): SPINRAZA has undergone extensive clinical trials to evaluate its efficacy and safety.
- [Who Could Benefit from SPINRAZA?](#): Details on the patient groups that may benefit from SPINRAZA treatment.
- [SPINRAZA Access](#): Information on accessing SPINRAZA therapy.
- [FAQs](#): Frequently asked questions about SPINRAZA.
- [HFMSE Scale](#): Explanation of the HFMSE scale used in SMA assessments.
- [Experience the Everyday](#): Insights into how SPINRAZA impacts daily life for patients.